ABSTRACT
Objective:To explore the multi-component， multi-target and multi-pathway mechanism of Astragali Radix against immunoglobulin A nephropathy （IgAN） by network pharmacology， aiming to provide evidence for its basic research and clinical application. Method:The active chemical components and targets of Astragali Radix and targets associated with IgAN were obtained by literature mining and GeneCards， Traditinal Chinese Medicine Integrated Database （TCMID）， Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform （TCMSP） databases. Cytoscape 3.7.1 software was used to draw network interaction diagrams. The key targets of Astragali Radix against IgAN were searched by network topology. Gene ontology （GO） analysis and Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway analysis involved in the targets were analyzed by different packages in R programming language. On this basis， cell experiments <italic>in vitro</italic> were carried out to verify the activation effect of astragaloside Ⅳ on phosphatidylinositol 3-kinase/protein kinase B/tumor suppressor gene protein 53 （PI3K/Akt/p53） signaling pathway of human mesangial cells. Result:A total of 25 active components and 49 ingredient-disease targets of Astragali Radix were screened. The GO enrichment analysis included 84 items， which were related to nuclear hormone receptor binding， nuclear receptor activity， deoxyribonucleic acid binding transcriptional activation activity and other aspects. The KEGG pathway enrichment analysis included 88 KEGG pathways， which were closely related to PI3K/Akt signaling pathway， hypoxia inducible factor-1 （HIF-1） signaling pathway， advanced glycation end product/receptor of advanced glycation end product （AGE/RAGE） signaling pathway and others. Cell experiments <italic>in vitro </italic>confirmed that astragaloside Ⅳ could effectively inhibit the platelet derived growth factor-BB （PDGF-BB）-induced proliferation of human mesangial cells by regulating PI3K/Akt/p53 signaling pathway. Conclusion:The active ingredients of Astragali Radix may play a role in the treatment of IgAN by acting on targets and pathways related to apoptosis， oxidative stress， inflammation response and others， providing ideas and directions for the new drug development and mechanism study of IgAN.
ABSTRACT
Objective To explore the common characters of sub-health and health risk factors among the public officials. Methods A total of 2776 public officials were tested using human energy monitor.The score differences of health risk factors and the differences of risk detection rates (moderate and above)between males and females were compared.Results The scores of 1 2 kinds of health risk factors by descending order were lack of energy(1.1 1 ±1.01 ),susceptible to fatigue (1.09 ±1.26),stuffy nose(0.95 ±1.59),chest tightness and shortness of breath (0.94 ±0.91 ),difficulty in falling asleep (0.89 ±1.59 ),lack of appetite (0.76 ±0.76 ),anxiety (0.75 ±1.1 6 ),oral inflammation (0.75 ±1.21 ), respiratory disorders (0.69 ±0.83),eye fatigue (0.61 ±0.72),backache and leg swelling (0.60 ±0.72),and stomach upset (0.48 ±0.65 ),respectively. The scores of women were significantly higher than those of men in 1 1 kinds of health risk factors(P<0.01 )except the score of anxiety (P>0.05 ).The risk detection rates (moderate and above)of women were significantly higher than that of men (P<0.01 )in the following 5 aspects:lack of energy,susceptible to fatigue, stuffy nose,mouth inflammation,and backache and leg swelling.Conclusion Chronic fatigue syndrome is the most common character of the sub-healthy public officials,and women are more prone to sub-health state.
ABSTRACT
<p><b>OBJECTIVE</b>To study on the efficacy, prognosis and security of high-intensity focused ultrasound (HIFU) combined with transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC).</p><p><b>METHODS</b>Totally 72 HCC patients treated by HIFU from December 2009 to January 2011 were divided into two groups according to treatment methods: 40 cases in HIFU group, 32 cases in TACE + HIFU treatment group (combined group). Then set up a control group include 40 cases treated by only TACE in the same period (TACE group). The improvement of clinical symptoms, AFP, reduce rate of tumor volume, survival rate of 1 year after operation and postoperative complications in front and behind the treatment were analyzed.</p><p><b>RESULTS</b>There was no significant statistical difference on the improvement of clinical symptoms in all these three groups (P > 0.05) after treatment for HCC. There is no significant statistical difference also on reduce rate of tumor volume and decrease rate of AFP in both HIFU group (35.0%, 41.4%) and TACE group (37.5%, 41.9%) (χ² = 0.054, P = 0.816; χ² = 0.002, P = 0.965). Both reduce rate of tumor volume (62.5%) and decrease rate of AFP (72.0%) in combined group were better than HIFU group (χ² = 5.394, P = 0.020; χ² = 5.098, P = 0.024) and TACE group (37.5%, 41.9%) (χ² = 4.448, P = 0.035; χ² = 5.062, P = 0.024). Kaplan-Meier survival curve showed that there was no significant statistical difference on short-term survival rate in the 3 groups. But the long-term survival rate of combined group was better than TACE group and HIFU group.</p><p><b>CONCLUSION</b>TACE combined with HIFU is a effective, safe and noninvasive treatment method to HCC.</p>